Amylyx reports Q2 net loss $54.1M; ALBRIOZA launched in Canada; FDA PDUFA Sept 29

Amylyx Pharmaceuticals, Inc.

2022-Q2 EPS reported -$1.85

Net loss of $54.1M ($0.93/sh) vs $21.9M ($3.41/sh) in Q2 2021; cash $206.7M at quarter end.
ALBRIOZA (AMX0035) commercially launched in Canada on July 29, 2022 – first product launch.
FDA Advisory Committee meeting for ALS NDA scheduled Sept 7, 2022; PDUFA action date Sept 29, 2022.
EU MAA under review; EMA decision expected first half 2023, with launch prep underway.
R&D expense $24.3M (up from $10.9M); G&A expense $30.0M (up from $7.7M) driven by commercial readiness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.